These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 7537123)

  • 61. Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells.
    Breems DA; van Hennik PB; Kusadasi N; Boudewijn A; Cornelissen JJ; Sonneveld P; Ploemacher RE
    Blood; 1996 Jun; 87(12):5370-8. PubMed ID: 8652852
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor.
    Tjønnfjord GE; Steen R; Evensen SA; Thorsby E; Egeland T
    Blood; 1994 Oct; 84(8):2795-801. PubMed ID: 7522643
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
    J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone?
    Roberts AW; Begley CG; Grigg AP; Basser RL
    Blood; 1995 Sep; 86(6):2451. PubMed ID: 7545026
    [No Abstract]   [Full Text] [Related]  

  • 65. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
    Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
    J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
    Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
    Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
    Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
    Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
    Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
    Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.
    Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Klersy C; Rusconi C; Colucci E; Lorenzi A; Troletti D; Consensi E; Lazzarino M
    Leuk Res; 2005 Feb; 29(2):159-63. PubMed ID: 15607364
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor.
    Berthou C; Marolleau JP; Lafaurie C; Soulié A; Dal Cortivo L; Bourge JF; Benbunan M; Sasportes M
    Blood; 1995 Nov; 86(9):3500-6. PubMed ID: 7579456
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield.
    Marques JF; Vigorito AC; Aranha FJ; Lorand-Metze I; Miranda EC; Lima Filho EC; Valbonesi M; Santini G; De Souza CA
    Transfus Sci; 2000 Oct; 23(2):91-100. PubMed ID: 11035269
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
    Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
    Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML.
    Heinzinger M; Waller CF; Rosenstiel A; Scheid S; Burger KJ; Lange W
    Leukemia; 1998 Mar; 12(3):333-9. PubMed ID: 9529127
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of peripheral blood CD34+ progenitor cells mobilized with chemotherapy and granulocyte colony-stimulating factor.
    Teofili L; Iovino MS; Sica S; Pierelli L; Menichella G; De Stefano V; Rumi C; Leone G
    Exp Hematol; 1994 Sep; 22(10):990-5. PubMed ID: 7522187
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection.
    Remacha AF; Martino R; Sureda A; Sarda MP; Solá C; Tugues D; Amill B; Garcia J; Oliver A
    Bone Marrow Transplant; 1996 Feb; 17(2):163-8. PubMed ID: 8640161
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in patients with lymphoma, myeloma and solid tumors.
    Efremidis AP; Koumakis G; Filis J; Moraki M; Vassilomanolakis M; Hatzichristou H; Barbounis V; Stamatellou M; Papanastasiou K; Kritsioti M; Plataniotis G; Arseni P
    Eur J Haematol; 1996 Oct; 57(4):269-77. PubMed ID: 8982289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.